

Immunmodulierende und immunsuppressive Therapie der Multiplen Sklerose

Zusammenfassung der aktualisierten Empfehlungen 2012

Traitement immunomodulateur et immunosuppresseur de la SEP

Résumé des recommandations actualisées pour l'année 2012

Literatur

- 1 Sellebjerg, F., et al., Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. *Neurology*, 1998. 51(2): p. 529–34.
- 2 Jacobs, L.D., et al., Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). *Ann Neurol*, 1996. 39(3): p. 285–94.
- 3 Simon, J.H., et al., Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. *Ann Neurol*, 1998. 43(1): p. 79–87.
- 4 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. *Neurology*, 1993. 43(4): p. 655–61.
- 5 Paty, D.W. and D.K. Li, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. *Neurology*, 1993. 43(4): p. 662–7.
- 6 Johnson, K.P., et al., Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. *Neurology*, 1995. 45(7): p. 1268–76.
- 7 Johnson, K.P., et al., Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. *Mult Scler*, 2000. 6(4): p. 255–66.
- 8 Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. *Lancet*, 1998. 352(9139): p. 1498–504.
- 9 Kappos, L., et al., A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med*. 362(5): p. 387–401.
- 10 Cohen, J.A., et al., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med*. 362(5): p. 402–15.
- 11 Polman, C.H., et al., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med*, 2006. 354(9): p. 899–910.
- 12 Rudick, R.A., et al., Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. *N Engl J Med*, 2006. 354(9): p. 911–23.
- 13 Hartung, H.P., et al., Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. *Lancet*, 2002. 360(9350): p. 2018–25.
- 14 Krapf, H., et al., Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. *Neurology*, 2005. 65(5): p. 690–5.
- 15 Kappos, L., et al., Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. *Neurology*, 2006. 67(7): p. 1242–9.
- 16 Kappos, L., et al., Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. *Lancet Neurol*, 2009. 8(11): p. 987–97.
- 17 Jacobs, L.D., et al., Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. *N Engl J Med*, 2000. 343(13): p. 898–904.
- 18 Goodin, D.S., IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. *Neurology*, 2006. 67(6): p. 1104; author reply 1104–5.

- 19 Comi, G., et al., Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. *Lancet*, 2009. 374(9700): p. 1503–11.
- 20 Comi, G., et al., Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. *Lancet Neurol*, 2012. 11(1): p. 33–41.
- 21 Bloomgren, G., et al., Risk of natalizumab-associated progressive multifocal leukoencephalopathy. *N Engl J Med*, 2012. 366(20): p. 1870–80.
- 22 Gorelik, L., et al., Anti-JC virus antibodies: implications for PML risk stratification. *Ann Neurol*, 2010. 68(3): p. 295–303.